Difference between revisions of "Teniposide (Vumon)"
Jump to navigation
Jump to search
(Created page with "==General information== Class/mechanism: <ref name="insert">[http://packageinserts.bms.com/pi/pi_vumon.pdf Teniposide (Vumon) package insert]</ref><ref>[http://hemonc.org/docs/pa...") |
|||
| Line 1: | Line 1: | ||
| + | Also known as VM-26. | ||
| + | |||
==General information== | ==General information== | ||
| − | Class/mechanism: <ref name="insert">[http://packageinserts.bms.com/pi/pi_vumon.pdf Teniposide (Vumon) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/teniposide.pdf Teniposide (Vumon) package insert (locally hosted backup)]</ref> | + | Class/mechanism: Topoisomerase inhibitor. Teniposide inhibits type II topoisomerase, which results in single and double-stranded DNA breaks and DNA-protein crosslinks. It is cell-cycle specific, acting in late S or early G2, preventing cells from entering mitosis. It is dissolved in Cremophor EL (polyoxyethylated castor oil), which may cause hypersensitivity infusion reactions.<ref name="insert">[http://packageinserts.bms.com/pi/pi_vumon.pdf Teniposide (Vumon) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/teniposide.pdf Teniposide (Vumon) package insert (locally hosted backup)]</ref> |
| − | <br>Route: | + | <br>Route: IV |
| − | <br>Extravasation: | + | <br>Extravasation: [[irritant]] |
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the package insert<ref name="insert"></ref>. | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the package insert<ref name="insert"></ref>. | ||
==Patient drug information== | ==Patient drug information== | ||
| − | *[http://chemocare.com/bio/teniposide. | + | *[http://chemocare.com/bio/teniposide.asp Teniposide (Vumon) patient drug information (Chemocare)]<ref>[http://chemocare.com/bio/teniposide.asp Teniposide (Vumon) patient drug information (Chemocare)]</ref> |
*[http://www.uptodate.com/contents/teniposide-patient-drug-information Teniposide (Vumon) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/teniposide-patient-drug-information Teniposide (Vumon) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/teniposide-patient-drug-information Teniposide (Vumon) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/teniposide-patient-drug-information Teniposide (Vumon) patient drug information (UpToDate)]</ref> | ||
==References== | ==References== | ||
<references/> | <references/> | ||
Revision as of 23:48, 24 February 2012
Also known as VM-26.
General information
Class/mechanism: Topoisomerase inhibitor. Teniposide inhibits type II topoisomerase, which results in single and double-stranded DNA breaks and DNA-protein crosslinks. It is cell-cycle specific, acting in late S or early G2, preventing cells from entering mitosis. It is dissolved in Cremophor EL (polyoxyethylated castor oil), which may cause hypersensitivity infusion reactions.[1][2]
Route: IV
Extravasation: irritant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the package insert[1].
Patient drug information
- Teniposide (Vumon) patient drug information (Chemocare)[3]
- Teniposide (Vumon) patient drug information (UpToDate)[4]